Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 235, doi. 10.1177/1740774518771347
- By:
- Publication type:
- Article
Works matching IS 17407745 AND DT 2018 AND VI 15 AND IP 3
Results: 14
1
2
Access versus evidence: The regulators’ dilemma.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 240, doi. 10.1177/1740774518770660
- By:
- Publication type:
- Article
3
The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 243, doi. 10.1177/1740774518770657
- By:
- Publication type:
- Article
4
Expediting drug development for serious illness: Trade-offs between patient access and certainty.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 230, doi. 10.1177/1740774518770656
- By:
- Publication type:
- Article
5
Expedited approval programs at the Food and Drug Administration.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 217, doi. 10.1177/1740774518770653
- By:
- Publication type:
- Article
6
The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 219, doi. 10.1177/1740774518770648
- By:
- Publication type:
- Article
7
A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 305, doi. 10.1177/1740774518769865
- By:
- Publication type:
- Article
8
LIBERTI: A SMART study in plastic surgery.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 286, doi. 10.1177/1740774518762435
- By:
- Publication type:
- Article
9
Reporting non-adherence in cluster randomised trials: A systematic review.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 294, doi. 10.1177/1740774518761666
- By:
- Publication type:
- Article
10
Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 278, doi. 10.1177/1740774518761627
- By:
- Publication type:
- Article
11
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 268, doi. 10.1177/1740774518761367
- By:
- Publication type:
- Article
12
The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 257, doi. 10.1177/1740774518760565
- By:
- Publication type:
- Article
13
Beyond total treatment effects in randomised controlled trials: Baseline measurement of intermediate outcomes needed to reduce confounding in mediation investigations.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 247, doi. 10.1177/1740774518760300
- By:
- Publication type:
- Article
14
Increasing the use of mobile technology–derived endpoints in clinical trials.
- Published in:
- Clinical Trials, 2018, v. 15, n. 3, p. 313, doi. 10.1177/1740774518755393
- By:
- Publication type:
- Article